Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

8.9%

258 terminated/withdrawn out of 2884 trials

Success Rate

89.5%

+2.9% vs industry average

Late-Stage Pipeline

33%

955 trials in Phase 3/4

Results Transparency

73%

1595 of 2197 completed trials have results

Key Signals

190 recruiting1595 with results212 terminated46 withdrawn

Enrollment Performance

Analytics

Phase 1

965(35.1%)

Phase 2

737(26.8%)

Phase 3

669(24.3%)

Phase 4

286(10.4%)

N/A

83(3.0%)

Early Phase 1

8(0.3%)

2748Total

Phase 1(965)

Phase 2(737)

Phase 3(669)

Phase 4(286)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2884)

Showing 20 of 2884 trials

NCT07686757Phase 4Enrolling By Invitation

INSIGHT-IBD Pragmatic Study

Role: collaborator

NCT06465069Phase 1Recruiting

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Role: lead

NCT03267732Phase 1Completed

A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)

Role: lead

NCT07856134Phase 4Not Yet Recruiting

AD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered Outcomes

Role: collaborator

NCT07153471Phase 3Active Not Recruiting

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

Role: lead

NCT07775300Phase 3Recruiting

A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

Role: lead

NCT07691489Phase 2Not Yet Recruiting

A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer

Role: collaborator

NCT06252675Phase 2Recruiting

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Role: collaborator

NCT06109311Phase 3Completed

A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

Role: lead

NCT06598943Phase 2Recruiting

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Role: lead

NCT07165002Phase 1Recruiting

A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment

Role: lead

NCT07783802Phase 2Recruiting

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

Role: lead

NCT06606106Phase 1Active Not Recruiting

A Study of LY3537031 in Overweight, Obese, and Healthy Participants

Role: lead

NCT07231952Phase 2Recruiting

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Role: collaborator

NCT06603571Phase 2Completed

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Role: lead

NCT05821959Phase 3Recruiting

Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss

Role: lead

NCT06945406Phase 1Recruiting

A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes

Role: lead

NCT07701083Phase 1Active Not Recruiting

A Study of Eloralintide (LY3841136) in Healthy Participants

Role: lead

NCT03994796Phase 2Active Not Recruiting

Genetic Testing in Guiding Treatment for Patients With Brain Metastases